References
- Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004;104:2655–2660.
- Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–1042.
- Gooley T, Chien J, Pergam S, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–2101.
- Cwynarski K, Roberts IA, Iacobelli S, et al. Paediatric and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;102:1224–1231.
- Muramatsu H, Kojima S, Yoshimi A, et al. Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Biol Blood Marrow Transplant. 2010;16:231–238.
- Hamidieh AA, Ansari S, Darbandi B, et al. The treatment of children suffering from chronic myelogenous leukemia: a comparison of the result of treatment with Imatinib mesylate and allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2013;17:380–386.
- Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006;20:187–192.
- Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010, use of tyrosine kinase inhibitors and stem cell transplantation. Review. Hematol Am Soc Hematol Educ Prog. 2010;2010:368–376.
- Schmid H, Jaeger B, Lohse J, et al. Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with Imatinib. Haematologica. 2009;94:1177–1179.
- Hobernicht SL, Schweiger B, Zeitler P, et al. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatr Blood Cancer. 2011;56:671–673.
- Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of Imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr. 2011;159:676–681.
- Bansal D, Shava U, Varma N, et al. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer. 2012;59:481–484.
- Millot F, Traore P, Guilhot J, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116:140–143.
- Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of Imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–522.
- Mahon FX, Rea D, Guilhot J, et al. Discontinuation of Imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035.